Ŭ·ÎºÎƼ³î ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2031³â)
Clobutinol Market Report: Trends, Forecast and Competitive Analysis to 2031
»óǰÄÚµå : 1815154
¸®¼­Ä¡»ç : Lucintel
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,850 £Ü 5,455,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,589,000
PDF (2 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,350 £Ü 7,581,000
PDF (5 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,050 £Ü 9,990,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ ±â¾÷ ³» ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ŭ·ÎºÎƼ³î ½ÃÀåÀÇ ¹Ì·¡´Â ÀǾàǰ ½ÃÀå°ú È­ÇÐÁ¦Ç° ½ÃÀå¿¡¼­ÀÇ ±âȸ·Î À¯¸ÁÇÕ´Ï´Ù. ¼¼°è Ŭ·ÎºÎƼ³î ½ÃÀåÀº 2025-2031³â µ¿¾È CAGR 6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº Á¦¾à ¿¬±¸ °³¹ß¿¡¼­ Ư¼ö È­ÇÐ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Æ´»õ È­ÇÐ »ê¾÷¿¡¼­ Á¤¹Ð È­ÇÐ ¹× Áß°£Ã¼¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù.

Ŭ·ÎºÎƼ³î ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ

Ŭ·ÎºÎƼ³î ½ÃÀåÀº ¾ÈÀü¼ºÀ» ÀÌÀ¯·Î Àü ¼¼°èÀûÀ¸·Î ÀǾàǰÀ¸·Î Àû¿ëÀÌ º¸·ùµÇ¾î Ä¡·áÁ¦·Î¼­ÀÇ È®´ë³ª ½Å±Ô ¿ëµµ µî ÀüÅëÀûÀÎ '»õ·Î¿î Æ®·»µå'´Â º¸ÀÌÁö ¾Ê°í ÀÖ½À´Ï´Ù. ¿ÀÈ÷·Á ÁÖ¸ñÇØ¾ß ÇÒ 'Æ®·»µå'´Â ÀǾàǰÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ ÈÄÇâÀû »ç¿ë »ç·Ê, ºñÁ¦¾à ºÐ¾ß¿¡¼­ÀÇ ÀáÀçÀû(¸Å¿ì Á¦ÇÑÀûÀÎ) ÀÀ¿ë, ¶Ç´Â ¾à¸®ÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ ´ëÇÑ ÇмúÀû ¿¬±¸ µîÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä µ¿ÇâÀº ÁÖ·ù ÀǾàǰ ½ÃÀå¿¡¼­ ¿©ÀüÈ÷ »ç¶óÁö°í ÀÖ´Ù´Â Á¡°ú ö¼ö¸¦ ÅëÇØ ¾òÀº ±³ÈÆÀÔ´Ï´Ù.

ÀÌ·¯ÇÑ Ãß¼¼¿Í ¸Â¹°·Á Ŭ·ÎºÎƼ³îÀº °ú°Å ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ Á¸ÀçÇÏÁö ¾Ê¾Ò´ø ÀǾàǰ ½ÃÀåÀ¸·Î ÀçÁ¤Àǵǰí ÀÖ½À´Ï´Ù. Ä¡·á¿ë¿¡¼­ ¹þ¾î³ª ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ÀϹÝÀû ±³ÈÆ, ¾à¹° ´ëüǰ, ¸Å¿ì Àü¹®ÀûÀÎ ºñÀÇ·áÀû ¿ëµµ·Î °ü½ÉÀÌ ¿Å°Ü°¡°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä Æ¯Â¡À¸·Î´Â ÅðÃâ°ú ÀÌ¿¡ µû¸¥ ¾ÈÀüÇÑ ´ëüǰÀÇ Çʿ伺, ±×¸®°í Á¦¾à ºÎ¹®ÀÇ ¾ö°ÝÇÑ ±ÔÁ¦¿¡ ´ëÇÑ ´ëó°¡ ÀÖ½À´Ï´Ù.

Ŭ·ÎºÎƼ³î ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

Ŭ·ÎºÎƼ³î ½ÃÀåÀº ÃÖ±Ù ±ØÀûÀÌ°í °áÁ¤ÀûÀÎ º¯È­¸¦ ¸ñ°ÝÇßÀ¸¸ç, ƯÈ÷ Àü ¼¼°èÀûÀ¸·Î ÀǾàǰ ¿ëµµ¿¡¼­ÀÇ Ã¶¼ö·Î Á¤ÀǵǴ ±ØÀûÀÎ º¯È­¸¦ ¸ñ°ÝÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶Ä¡´Â ½ÉÀå ¾ÈÀü¼º ¿ì·Á °¡´É¼ºÀ» ÀÔÁõÇÑ ÀÓ»ó Áõ°ÅÀÇ °³Á¤¿¡ ´ëÇÑ Á÷Á¢ÀûÀÎ ¹ÝÀÀÀ̾ú½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â Àü ¼¼°è ±ÔÁ¦ ´ç±¹°ú Á¦¾àȸ»çµéÀÇ È¯ÀÚ º¸È£¿¡ ´ëÇÑ °­ÇÑ °ü½ÉÀÇ Ç¥ÇöÀ̸ç, Ŭ·ÎºÎƼ³îÀÇ »ó¾÷Àû ÀáÀç·Â°ú Ä¡·á ±â´É¿¡ ´ëÇÑ Ã¶ÀúÇÑ ÀçÆò°¡¸¦ ºÒ·¯ÀÏÀ¸Ä×½À´Ï´Ù.

ÀÌ·¯ÇÑ »ç°ÇµéÀº Ŭ·ÎºÎƼ³îÀÇ ÁöÀ§¸¦ ÀǾàǰ¿¡¼­ ÀǾàǰ ½ÃÀå¿¡ ºÎºÐÀûÀ¸·Î Á¸ÀçÇÏÁö ¾Ê´Â ÀǾàǰÀ¸·Î ±Ùº»ÀûÀ¸·Î º¯È­½ÃÅ´À¸·Î½á Ŭ·ÎºÎƼ³î ½ÃÀå¿¡ ´©ÀûÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±× °á°ú, Ŭ·ÎºÎƼ³îÀº Àü ¼¼°èÀûÀ¸·Î ÆÇ¸Å°¡ ÁߴܵǾú°í, ÁøÇØÁ¦ ½ÃÀåÀÇ ÃÊÁ¡Àº ´õ ¾ÈÀüÇÑ ´ëü ¾à¹°°ú ´Ù¸¥ Ä¡·á¹ýÀ¸·Î ¿Å°ÜÁ³½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®

Á¦4Àå À¯Çüº° Ŭ·ÎºÎƼ³î ½ÃÀå

Á¦5Àå ¿ëµµº° Ŭ·ÎºÎƼ³î ½ÃÀå

Á¦6Àå Áö¿ª ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ Å¬·ÎºÎƼ³î ½ÃÀå

Á¦8Àå À¯·´ÀÇ Å¬·ÎºÎƼ³î ½ÃÀå

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Å¬·ÎºÎƼ³î ½ÃÀå

Á¦10Àå ±âŸ Áö¿ªÀÇ Å¬·ÎºÎƼ³î ½ÃÀå

Á¦11Àå °æÀï ºÐ¼®

Á¦12Àå ±âȸ¿Í Àü·« ºÐ¼®

Á¦13Àå ¹ë·ùüÀÎ Àüü¿¡ °ÉÄ£ ÁÖ¿ä ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The future of the global clobutinol market looks promising with opportunities in the medicine and chemical markets. The global clobutinol market is expected to grow with a CAGR of 6% from 2025 to 2031. The major drivers for this market are the rising demand for specialized chemical reagents in pharmaceutical research & development and the increasing need for fine chemicals & intermediates in niche chemical industries.

Emerging Trends in the Clobutinol Market

The clobutinol market, having been withdrawn globally from medicinal application on grounds of safety, is not witnessing conventional "emerging trends" in terms of expansion or novel applications as a therapeutic. Rather, any notable "trends" would pertain to being a retrospective case study on drug safety, its potential (extremely limited) applications in non-pharmaceutical areas, or scholarly investigation of its pharmacological profile. The main trend is its ongoing absence from mainstream pharmaceutical markets and the lessons that were learned from withdrawal.

All these trends together are redefining the Clobutinol as a nonexistent drug market through past safety concerns. The attention has moved away from its therapeutic use and towards general lessons in drug safety, alternatives to medication, and extremely specialized non-medical applications. The market is mainly characterized by its withdrawal and the resulting necessity for safer alternatives and rigorous regulatory efforts within the pharmaceutical sector.

Recent Developments in the Clobutinol Market

The clobutinol market has witnessed dramatic and conclusive recent changes, particularly defined by its worldwide withdrawal from pharmaceutical application. These measures were a direct reaction to revised clinical evidence that established possible cardiac safety concerns. The changes indicate an intense focus on patient protection within world regulatory agencies and pharmaceutical corporations, which resulted in a thorough re-assessment of Clobutinol's commercial potential and therapeutic function.

These events have cumulatively affected the clobutinol market by fundamentally changing its status from a medicinal to a drug that is partially non-existent on pharmaceutical markets. The general effect is an affirmation of the absolutely foremost significance of drug safety, resulting in its global withdrawal and a consequent change of focus in the antitussive market towards safer alternatives and other therapeutic options.

Strategic Growth Opportunities in the Clobutinol Market

The growth prospects in the clobutinol market are in effect nonexistent for its past use as a cough suppressant because of its worldwide withdrawal for cardiac safety issues. Hence, talking about "growth opportunities by application" in the conventional sense would not be accurate. Any "opportunities" involving Clobutinol would be in ancillary areas like research, regulatory insights, or highly niche non-medical applications, and not a profitable pharmaceutical market.

These extremely specialized "opportunities" are affecting the Clobutinol by consolidating its position as a drug that has been withdrawn from general medical use because of safety issues. The effect is one of redirection from its direct therapeutic use to its use as a research tool, a classic case study, and an impetus for enhancing drug safety and regulatory habits in the wider pharmaceutical community.

Clobutinol Market Driver and Challenges

Due to the withdrawal of Clobutinol market from general sale in most markets on safety grounds, traditional analysis of "drivers and challenges" for its market in terms of expansion or commercial viability is not fitting. Rather, the "drivers" would be reasons for its withdrawal, and the "challenges" would be the effects of that withdrawal or the reasons it is no longer available on the market.

The factors responsible for driving the clobutinol market include:

1. Risk Discovery of Cardiac Arrhythmia: The strongest incentive for the market downturn was the discovery of a possible risk of cardiac arrhythmia, i.e., QT prolongation, by way of post-market monitoring and fresh clinical trials. The safety issue had a direct bearing on the regulatory warning that followed withdrawal. The implication here is a shift in the risk-benefit paradigm of the drug, wherein its medicinal use is no longer viable.

2. Proactive Regulatory Actions and Patient Safety Emphasis: The regulatory agencies, especially in Europe, acted quickly and firmly, issuing warnings and withdrawing marketing authorizations based on the new safety information. This proactive action by regulators, putting patient safety above availability in the market, was a key factor in the withdrawal of Clobutinol. This suggests a strengthening of high-quality drug safety measures across the world.

3. Voluntary Withdrawal by the Maker (Boehringer Ingelheim): The voluntary action by Boehringer Ingelheim, the main maker, to withdraw Clobutinol products from all markets was critical. This action, on their own safety evaluations, showed corporate responsibility and facilitated the removal of the drug. The inference is that drug makers tend to act ahead of or in coordination with regulatory action when there are major safety issues.

4. Availability of Safer Alternative Antitussives: The marketplace had plenty of other safe and effective cough suppressants to choose from, including dextromethorphan and codeine (where still on the market and utilized for cough). Availability of these alternatives would mean that de-authorization of Clobutinol did not leave an unmet medical need. The suggestion would be that the marketplace readily accommodated the loss of Clobutinol without excessive cough management disruption.

5. Increased Pharmacovigilance and Post-Market Monitoring: The Clobutinol example was a high-profile instance of the necessity of ongoing pharmacovigilance and post-market monitoring for any drug, including ones that have been in use for many years. The system successfully detected a severe safety problem that did not manifest during early trials. The implication is an increased strengthening of drug safety monitoring around the world, resulting in earlier identification of possible issues.

Challenges in the clobutinol market are:

1. Non-existent Commercial Market for Medicinal Use: The main problem is that there practically does not exist any legitimate commercial market for Clobutinol as a cough suppressant in most developed nations as it has been withdrawn. Demand would be very niche or illegal. The implication is that previous producers and sellers have closed down any operations on its medicinal product, and hence, conventional market analysis does not apply.

2. Reputational Harm and Loss of Trust: A withdrawal of a highly popular drug because of safety issues can result in reputational harm to the original company and may also cause a loss of public trust in drug safety procedures, even though ultimately the withdrawal proved to be for the good. The connotation is a lasting test for the pharmaceutical sector to keep public trust in drug safety and regulation intact.

3. Healthcare Providers and Patients Disruption (during withdrawal): Although alternatives may have been available, the abrupt withdrawal of a widely used or over-the-counter drug might temporarily have disrupted healthcare providers' prescribing practices and patients who were habituated to using it. The implication here is the real-world difficulty of managing drug discontinuations in practice, even with safety justification.

In summary, the analysis of the clobutinol market is special insofar as its course was dominated by safety issues. Its discovery of risk to cardiac arrhythmia, anticipatory regulatory action, and voluntary withdrawal by the manufacturer were dominant "drivers" to its rapid fall from medical usage. Thus, the "challenges" presently hinge on its non-existent market for commercial purposes, the remaining impact of a withdrawn drug on industry image, and lessons learned in pharmacovigilance. This case highlights the utmost significance of patient safety within the pharmaceutical business, essentially transforming the existence of the drug to near zero.

List of Clobutinol Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies clobutinol companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the clobutinol companies profiled in this report include-

Clobutinol Market by Segment

The study includes a forecast for the global clobutinol market by type, application, and region.

Clobutinol Market by Type [Value from 2019 to 2031]:

Clobutinol Market by Application [Value from 2019 to 2031]:

Clobutinol Market by Region [Value from 2019 to 2031]:

Country Wise Outlook for the Clobutinol Market

The market for clobutinol has dramatically shifted over the last few years, mainly as a result of safety issues causing its withdrawal from most international markets. Traditionally applied as an antitussive, Clobutinol became very popular, but recent clinical discoveries identified a possible risk of cardiac arrhythmia. These events have had a deeply affecting role in its availability and commercial feasibility, turning it from a ubiquitous over-the-counter or prescription drug into a substance that has very little or no immediate market presence in the majority of developed countries. An appreciation of these changes calls for analyzing particular regulatory measures and active research in the major areas.

Features of the Global Clobutinol Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Market Overview

3. Market Trends & Forecast Analysis

4. Global Clobutinol Market by Type

5. Global Clobutinol Market by Application

6. Regional Analysis

7. North American Clobutinol Market

8. European Clobutinol Market

9. APAC Clobutinol Market

10. ROW Clobutinol Market

11. Competitor Analysis

12. Opportunities & Strategic Analysis

13. Company Profiles of the Leading Players Across the Value Chain

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â